

SelectMDx cost-effective in four European countries

October 2018—MDxHealth announced that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer has been published in *Prostate Cancer and Prostatic Diseases* (Govers TM, et al. Epub ahead of print Aug. 20, 2018. doi:10.1038/s41391-018-0076-3).

The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a population of men from France, Germany, Italy, and Spain with elevated prostate specific antigen. The model used in the study compared the current standard of care, in which men undergo initial prostate biopsy in the case of an elevated PSA, with a strategy in which SelectMDx is used to select men for biopsy based on the probability of them harboring the aggressive form of prostate cancer.

In all four countries, the use of SelectMDx resulted in quality-adjusted life year gains and cost savings. In France, SelectMDx resulted in 0.022 QALYs gained at a cost savings of €1,217 per patient. For Germany, the model showed a QALY gain of 0.016 and a cost savings of €442. In Italy, the QALY gain and cost savings were 0.031 and €762. In Spain 0.020 QALYs were gained and €250 costs were saved. The implementation of SelectMDx in the four countries was shown to reduce the number of biopsies for initial diagnosis and prevent unnecessary overtreatment. The potential total cost savings for the health care providers in those EU countries is more than €300 million (approximately \$350 million) for each annual cohort under this new standard of care, the company reported.

[MDxHealth](#), 866-259-5644